Communiqués Unicycive Therapeutics, Inc.

Actions

UNCY

US90466Y2028

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
5,630 ^USD	+3,30 %		+2,18 %	-2,43 %

13/08	Unicycive Therapeutics, Inc. : B. Riley toujours positif	ZM
12/08	Unicycive Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

12/08	Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update	AQ
06/07	Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses	NE
02/07	UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton	NE
30/06	Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)	AQ
14/05	Unicycive Therapeutics : May 2026 Corporate Presentation	PU
12/05	Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update	AQ
04/05	Unicycive Therapeutics : May 2026 Corporate Presentation	PU
09/04	Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
30/03	Unicycive Therapeutics : March 2026 Corporate Presentation	PU
30/03	Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update	AQ
06/03	Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm	NE
05/03	Unicycive Therapeutics : March 2026 Corporate Presentation	PU
17/02	Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf	NE
06/02	Unicycive Therapeutics : February 2026 Corporate Presentation	PU
04/02	Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit	AQ
30/01	Unicycive Therapeutics : January 2026 Corporate Presentation	PU
29/01	Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission	AQ
07/01	Unicycive Therapeutics : January 2026 Corporate Presentation	PU
29/12	Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)	AQ
01/12	Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf	NE
25/11	Unicycive Therapeutics to Participate in Upcoming Investor Events in December	AQ
12/11	Unicycive Therapeutics : November 2025 Corporate Presentation	PU
12/11	Unicycive Therapeutics : Earnings Release Q3 2025	PU
12/11	Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update	AQ
03/11	Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference	AQ